Kathiresan Sekar

SEC source: 0001864112-25-000004 · form4-09242025_080928.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 18,000 shares

Expires 2035-09-21

F1 · derivative.exercise_date: The option shall vest as to 1/9 of the total award monthly with the first tranche vesting on October 1, 2025, subject to the reporting person's continued service to the Issuer on the applicable vesting date.

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 13

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 526,000 shares

Expires not disclosed

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (each such option, a "Closing Date Contingent Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Closing Date Contingent Option, and each holder of such Closing Date Contingent Option is entitled to receive (without interest) an amount in cash (less any applicable tax withholdings) equal to the product of (i) the total number of shares of the Issuer's Common Stock subject to such Closing Date Contingent Option immediately prior to the Effective Time multiplied by (ii) the cash payment a holder of one CVR would receive, and when such payments are made to the holders of CVRs (without regard to vesting);

F7 · price: (continued from footnote 6) provided that each such Closing Date Contingent Option shall only receive the excess of the sum of (x) the Cash Consideration plus (y) the Milestone Payment over the applicable exercise price of such Closing Date Contingent Option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (each such option, a "Closing Date Contingent Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Closing Date Contingent Option, and each holder of such Closing Date Contingent Option is entitled to receive (without interest) an amount in cash (less any applicable tax withholdings) equal to the product of (i) the total number of shares of the Issuer's Common Stock subject to such Closing Date Contingent Option immediately prior to the Effective Time multiplied by (ii) the cash payment a holder of one CVR would receive, and when such payments are made to the holders of CVRs (without regard to vesting);

F7 · derivative.exercise_date: (continued from footnote 6) provided that each such Closing Date Contingent Option shall only receive the excess of the sum of (x) the Cash Consideration plus (y) the Milestone Payment over the applicable exercise price of such Closing Date Contingent Option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Stock Option having an exercise price equal to or greater than the Cash Consideration and less than the sum of the Cash Consideration and the Milestone Payment (each such option, a "Closing Date Contingent Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Closing Date Contingent Option, and each holder of such Closing Date Contingent Option is entitled to receive (without interest) an amount in cash (less any applicable tax withholdings) equal to the product of (i) the total number of shares of the Issuer's Common Stock subject to such Closing Date Contingent Option immediately prior to the Effective Time multiplied by (ii) the cash payment a holder of one CVR would receive, and when such payments are made to the holders of CVRs (without regard to vesting);

F7 · derivative.expiration_date: (continued from footnote 6) provided that each such Closing Date Contingent Option shall only receive the excess of the sum of (x) the Cash Consideration plus (y) the Milestone Payment over the applicable exercise price of such Closing Date Contingent Option.

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 12

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 431,988 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 11

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Sekar Kathiresan 2023 Annuity Trust

Disclosed balance after: 0

Underlying: Common Stock · 75,105 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 10

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 500,203 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 9

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 167,425 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 8

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 138,995 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 7

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 99,000 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit ("RSU") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit ("RSU") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit ("RSU") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU.

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 6

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 120,000 shares

Expires not disclosed

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit ("RSU") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU.

F5 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit ("RSU") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU.

F5 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested Restricted Stock Unit ("RSU") that is outstanding immediately prior to the Effective Time was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any RSU, and each such holder of such RSU received (without interest) (x) an amount in cash (less any applicable tax withholdings) equal to the product of the Cash Consideration multiplied by the total number of Shares subject to such RSU and (y) one CVR for each RSU.

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 5

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · derivative · entry 4

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 488,000 shares

Expires not disclosed

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

F4 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding stock option of Issuer having an exercise price less than the Cash Consideration (each such option, a "Cash-Out Stock Option") that is outstanding immediately prior to the Effective Time, whether or not vested, was automatically cancelled, by virtue of the Merger and without any action on the part of any holder of any Cash-Out Stock Option, and each holder of such Cash-Out Stock Option received (without interest) (i) an amount in cash (less any applicable tax withholdings) equal to the product of (a) the excess, if any, of the Cash Consideration over the applicable exercise price per share underlying such Cash-Out Stock Option multiplied by (b) the total number of shares of the Issuer's Common Stock subject to such Cash-Out Stock Option and (ii) one CVR for each share subject to such Cash-Out Stock Option (without regard to vesting).

SEC source: 0000950170-25-099260 · ownership.xml · nonDerivative · entry 3

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Kathiresan Family 2021 Irrevocable Trust

Disclosed balance after: 0

F1 · kind: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest

F2 · kind: (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest

F2 · price: (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

SEC source: 0000950170-25-099260 · ownership.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Sekar Kathiresan 2021 Irrevocable Trust

Disclosed balance after: 0

F1 · kind: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest

F2 · kind: (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest

F2 · price: (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

SEC source: 0000950170-25-099260 · ownership.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest

F2 · kind: (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

F3 · shares: Includes 1,745 shares of the Company's common stock acquired in 2025 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.

F1 · price: In connection with the terms of an Agreement and Plan of Merger, dated as of June 16, 2025 (the "Merger Agreement"), by and among the Issuer, Eli Lilly and Company ("Parent") and Parent's indirect wholly owned subsidiary, Ridgeway Acquisition Corporation ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $10.50 per share in cash, without interest and less any applicable tax withholding (the "Cash Consideration"); plus (ii) one non-tradable contingent value right (each, a "CVR"), which represents the contractual right to receive a contingent payment of up to $3.00 per CVR, net to the stockholder in cash, without interest

F2 · price: (continued from footnote 1) and less any applicable tax withholding, upon the achievement of a certain specified milestone relating to the Issuer's business (the "Milestone Payment"), in accordance with the terms and subject to the conditions of a contingent value rights agreement entered by and among Parent, the Purchaser, and Computershare Inc. and its affiliate, Computershare Trust Company, N.A., as the rights agent. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of July 25, 2025, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time").

SEC source: 0000950170-25-083310 · ownership.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,681

Underlying: Common Stock · 136,681 shares

Expires 2035-06-05

F1 · derivative.exercise_date: This option was granted on June 6, 2025 with respect to 136,681 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0000950170-25-050563 · ownership.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 346,686

F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 18, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-050563 · ownership.xml · derivative · entry 5

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 99,000

Underlying: Common Stock · 33,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

F3 · derivative.exercise_date: On February 14, 2024, the reporting person was granted 132,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.

F3 · derivative.expiration_date: On February 14, 2024, the reporting person was granted 132,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.

SEC source: 0000950170-25-050563 · ownership.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 356,508

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.

SEC source: 0000950170-25-003854 · ownership.xml · derivative · entry 3

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2035-01-07

F4 · derivative.exercise_date: The option was granted on January 8, 2025. 100% of the shares underlying the option will vest immediately if and when the last quoted trading price per share of the Company's common stock on the Nasdaq Global Select Market is equal to or greater than $20.00 for at least 15 consecutive trading days on or prior to the second anniversary of the grant date.

SEC source: 0000950170-25-003854 · ownership.xml · derivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3 · derivative.exercise_date: On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.

F3 · derivative.expiration_date: On January 8, 2025, the reporting person was granted restricted stock units, vesting in three equal annual installments, beginning on April 1, 2026, and the remaining two installments vesting on April 1, 2027 and April 1, 2028.

SEC source: 0000950170-25-003854 · ownership.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 488,000

Underlying: Common Stock · 488,000 shares

Expires 2035-01-07

F1 · derivative.exercise_date: The option was granted on January 8, 2025. 25% of the shares underlying the option will vest on January 8, 2026, and the remainder are scheduled to vest in equal monthly installments thereafter until January 8, 2029.

SEC source: 0000950170-24-133290 · ownership.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Sekar Kathiresan 2021 Irrevocable Trust

Disclosed balance after: 110,997

F1 · shares: On December 4, 2024, the reporting person transferred 30,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.

F1 · balance_after: On December 4, 2024, the reporting person transferred 30,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.

SEC source: 0000950170-24-133290 · ownership.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 323,508

F1 · shares: On December 4, 2024, the reporting person transferred 30,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.

F2 · balance_after: Includes 2,380 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.

SEC source: 0000950170-24-080012 · ownership.xml · derivative · entry 4

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 215,308

Underlying: Common Stock · 30,000 shares

Expires 2030-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.

SEC source: 0000950170-24-080012 · ownership.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,128

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 4,918 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.

SEC source: 0000950170-24-069557 · ownership.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,225

Underlying: Common Stock · 102,225 shares

Expires 2034-06-02

F1 · derivative.exercise_date: This option was granted on June 3, 2024 with respect to 102,225 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0000950170-24-016423 · ownership.xml · derivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,000

Underlying: Common Stock · 132,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3 · derivative.exercise_date: On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.

F3 · derivative.expiration_date: On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028.

SEC source: 0000950170-24-016423 · ownership.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 526,000

Underlying: Common Stock · 526,000 shares

Expires 2034-02-13

F1 · derivative.exercise_date: The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028.

SEC source: 0001209191-23-033438 · doc4.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,055

Underlying: Common Stock · 66,055 shares

Expires 2033-05-30

F1 · derivative.exercise_date: This option was granted on May 31, 2023 with respect to 66,055 shares of the Issuer's common stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant date.

SEC source: 0001209191-23-010123 · doc4.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 550,200

Underlying: Common Stock · 550,200 shares

Expires 2033-02-13

F1 · derivative.exercise_date: The option was granted on February 14, 2023. 25% of the shares underlying the option will vest on February 14, 2024, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2027.

SEC source: 0001209191-22-052799 · doc4.xml · derivative · entry 7

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 138,995

Underlying: Common Stock · 50,000 shares

Expires 2029-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The remaining shares underlying this option, which was granted on April 15, 2019, vest in equal monthly installments until March 25, 2024.

SEC source: 0001209191-22-052799 · doc4.xml · nonDerivative · entry 4

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,839

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.61 to $35.50, inclusive.

SEC source: 0001209191-22-052799 · doc4.xml · nonDerivative · entry 3

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 327,743

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.59 to $34.59, inclusive.

SEC source: 0001209191-22-052799 · doc4.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,928

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.59 to $33.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), and (4) of this Form 4.

SEC source: 0001209191-22-052799 · doc4.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-045447 · doc4.xml · derivative · entry 5

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 167,425

Underlying: Common Stock · 50,000 shares

Expires 2029-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.

SEC source: 0001209191-22-045447 · doc4.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,839

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.

SEC source: 0001209191-22-045447 · doc4.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-22-026903 · doc4.xml · derivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,881

Underlying: Common Stock · 71,881 shares

Expires 2032-07-24

F1 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments after July 25, 2022, subject to the reporting person's continued service with the Issuer through each vesting date.

SEC source: 0001209191-22-042871 · doc4.xml · derivative · entry 5

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,425

Underlying: Common Stock · 50,000 shares

Expires 2029-04-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.

SEC source: 0001209191-22-042871 · doc4.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,839

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 21, 2022.

SEC source: 0001209191-22-042871 · doc4.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 367,839

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-22-042265 · doc4.xml · derivative · entry 7

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Sekar Kathiresan 2022 Annuity Trust

Disclosed balance after: 300,000

Underlying: Common Stock · 160,000 shares

Expires 2030-09-15

F7 · derivative.exercise_date: The shares underlying the option being transferred were fully vested as of the date of transfer.

F5 · balance_after: On July 12, 2022, the reporting person transferred an employee stock option to purchase 160,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.

SEC source: 0001209191-22-042265 · doc4.xml · derivative · entry 6

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Sekar Kathiresan 2022 Annuity Trust

Disclosed balance after: 140,000

Underlying: Common Stock · 140,000 shares

Expires 2031-02-11

F7 · derivative.exercise_date: The shares underlying the option being transferred were fully vested as of the date of transfer.

F3 · balance_after: On July 12, 2022, the reporting person transferred an employee stock option to purchase 140,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.

SEC source: 0001209191-22-042265 · doc4.xml · derivative · entry 5

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 445,308

Underlying: Common Stock · 160,000 shares

Expires 2030-09-15

F5 · kind: On July 12, 2022, the reporting person transferred an employee stock option to purchase 160,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.

F6 · derivative.exercise_date: The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.

SEC source: 0001209191-22-042265 · doc4.xml · derivative · entry 4

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 291,988

Underlying: Common Stock · 140,000 shares

Expires 2031-02-11

F3 · kind: On July 12, 2022, the reporting person transferred an employee stock option to purchase 140,000 shares of common stock of the Company to a grantor retained annuity trust of which the reporting person is trustee. The reporting person and members of his immediate family are the sole beneficiaries of the trust.

F4 · derivative.exercise_date: The remaining shares underlying this option, which was granted on February 12, 2021, vest in equal monthly installments until February 1, 2025.

SEC source: 0001209191-22-042265 · doc4.xml · nonDerivative · entry 2

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Kathiresan Family 2021 Irrevocable Trust

Disclosed balance after: 240,997

F1 · shares: On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.

F1 · balance_after: On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.

SEC source: 0001209191-22-042265 · doc4.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 317,839

F1 · shares: On July 7, 2022, the reporting person transferred 160,000 shares of Verve Therapeutics, Inc. (the "Company") common stock to a family trust. Members of the reporting person's immediate family are the beneficiaries of the trust.

F2 · balance_after: Includes 314 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.

SEC source: 0000899243-22-011767 · doc4.xml · derivative · entry 4

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 605,308

Underlying: Common Stock · 69,674 shares

Expires 2030-09-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.

SEC source: 0000899243-22-011767 · doc4.xml · nonDerivative · entry 1

Kathiresan Sekar · CIK 0001864112 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 477,525

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,315 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.